Professors Sir David and Birgit Lane to Resume Full-Time Appointments in Singapore
News May 22, 2009
Professor Sir David Lane and Professor Birgit Lane are to leave the University of Dundee and take up full-time appointments with the Agency for Science, Technology and Research in Singapore from 1st September 2009.
Sir David Lane will resume his position as Chief Scientist to the Agency for Science, Technology and Research. Birgit Lane will resume full-time duties as Executive Director of the Institute of Medical Biology at the Agency, which she helped to establish.
Both previously worked in Singapore while on sabbatical leave from the University of Dundee, Scotland, from 2005-2007. They returned to Dundee in late 2007 and helped establish an innovative interdisciplinary research division, the Division of Molecular Medicine, together with Professor Irwin McLean.
“It is inevitable that from time to time we will see senior staff leave, and we wish David and Birgit well in Singapore,” said Professor Peter Downes, Acting Principal of the University of Dundee.
“We appreciate all the work they have done in Dundee, most recently in helping establish the Division of Molecular Medicine, which will continue to grow and develop under the leadership of Professor Irwin McLean, discoverer of filaggrin gene mutations which have been shown to be a cause of eczema and some forms of asthma.
“We have a great ability in Dundee to recruit world class scientists to enhance our position as a centre of excellence in Europe for research in biomedical and biological sciences and we are confident of our ability to continue to do so.”
David and Birgit Lane said they see the University of Dundee as “one of the best places to do translational biomedical science in the UK”.
They will continue to promote their UK links and will retain their productive Dundee collaborations in Singapore.
The Lanes’ arrival in Singapore in 2005 began a strong connection between the Agency for Science, Technology and Research and the University of Dundee - one of the UK’s top life sciences institutes - and the heads of the two institutions signed an agreement for co-training of students in 2006 which has developed into a growing body of jointly supervised research students, regular joint scientific symposia, sharing of teaching practices and many research collaborations.
Sir David will continue in his current position as Cancer Research UK’s Chief Scientist.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.